UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 14,898 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lowered its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 5.9% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 236,222 shares of the biopharmaceutical company’s stock after selling 14,898 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.20% of Catalyst Pharmaceuticals worth $4,696,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of CPRX. Cetera Advisors LLC purchased a new stake in shares of Catalyst Pharmaceuticals in the first quarter worth approximately $401,000. CWM LLC grew its position in Catalyst Pharmaceuticals by 686.5% in the 2nd quarter. CWM LLC now owns 4,066 shares of the biopharmaceutical company’s stock worth $63,000 after purchasing an additional 3,549 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its stake in Catalyst Pharmaceuticals by 12.5% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 18,028 shares of the biopharmaceutical company’s stock valued at $279,000 after buying an additional 2,002 shares during the last quarter. Louisiana State Employees Retirement System lifted its position in shares of Catalyst Pharmaceuticals by 2.2% during the 2nd quarter. Louisiana State Employees Retirement System now owns 56,500 shares of the biopharmaceutical company’s stock worth $875,000 after buying an additional 1,200 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its holdings in shares of Catalyst Pharmaceuticals by 2.1% in the second quarter. Bank of New York Mellon Corp now owns 834,415 shares of the biopharmaceutical company’s stock valued at $12,925,000 after acquiring an additional 16,960 shares in the last quarter. Institutional investors and hedge funds own 79.22% of the company’s stock.

Insider Transactions at Catalyst Pharmaceuticals

In other news, insider Gary Ingenito sold 12,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $22.72, for a total transaction of $272,640.00. Following the sale, the insider now directly owns 51,391 shares of the company’s stock, valued at $1,167,603.52. This represents a 18.93 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Molly Harper sold 17,500 shares of the stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $22.00, for a total transaction of $385,000.00. The disclosure for this sale can be found here. Insiders have sold 79,500 shares of company stock worth $1,754,140 in the last 90 days. 11.00% of the stock is currently owned by insiders.

Catalyst Pharmaceuticals Stock Performance

CPRX opened at $21.97 on Thursday. The company’s 50-day simple moving average is $21.56 and its two-hundred day simple moving average is $19.09. The stock has a market capitalization of $2.62 billion, a P/E ratio of 18.62, a P/E/G ratio of 3.36 and a beta of 0.75. Catalyst Pharmaceuticals, Inc. has a 52-week low of $13.00 and a 52-week high of $24.27.

Analyst Ratings Changes

A number of analysts have issued reports on the company. Stephens started coverage on Catalyst Pharmaceuticals in a research report on Monday, November 18th. They issued an “overweight” rating and a $35.00 target price for the company. Truist Financial boosted their price objective on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a research note on Monday, November 11th. Finally, HC Wainwright reiterated a “buy” rating and set a $30.00 target price on shares of Catalyst Pharmaceuticals in a research report on Friday, November 8th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $31.14.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.